CHE · Chemed Corp

Track CHE — free

$523.38 +3.11 (+0.60%) At close · Aug 28

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$6.84B

13.07M

Up next

Next earnings call

Oct 31, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 31, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 14.4 · calm Equity put/call 0.62

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +17%

above

Price vs 50-day avg +3%

above

RSI (14) 47

neutral

MACD trend Negative

52-week position 84%

mid-range

Momentum

relative strength

Very Strong

1-month return −2%

trailing

6-month return +30%

trailing

YTD return +22%

this year

Relative strength +16%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $509 › 200d $446 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +103 funds added

Insider flow Distributing

Net -$3.4M over 90 days · 100% sells

Short interest Rising

4.88% of float · ▲ +38.4% MoM · 3.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

533 holders — mid 3-yr range

Squeeze score 65

elevated · 0–100

Fundamentals

Strong

Revenue growth +4%

Y/Y

EPS growth −8%

Y/Y

Free cash flow $325.5M

Buyback $139.8M

remaining

Balance sheet $23.4M

net debt

Quant / Vol

risk profile

Moderate

Volatility 29%

annualized · 1-yr

Max drawdown −23%

past year

ATR 2.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 28, 2026

full year

Adjusted EBITDA margin Non-GAAP 21.5% – 22.5%

Roto-Rooter adjusted EBITDA margin 21.5% – 22.5%

full-year 2026

Earnings per diluted share, excluding non-cash expenses for stoc Non-GAAP Maintained $25.00 – $25.75

Jun 30, 2026 $25.00 – $25.75 Jul 28, 2026 $25.00 – $25.75

revised guidance

Effective corporate tax rate on adjusted earnings Non-GAAP 24.5%

Prior guidance period ended · from the 8-K filed Oct 28, 2025

Adjusted Diluted EPS, excluding non-cash expense for stock optio · 2025 $22.00 – $22.30

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+17% Bullish

Price vs 50-day avg

+3% Bullish

RSI (14)

47 Neutral

MACD trend

Negative Bearish

52-week position

84% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $509 › 200d $446 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +103 funds added

Insider flow Distributing

Net -$3.4M over 90 days · 100% sells

Short interest Rising

4.88% of float · ▲ +38.4% MoM · 3.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

533 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $369 Now $523 · 84% Range high $553

vs 200-day avg +17% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$238.06M	Six Months Ended June 30, 2026	—
Adjusted EBITDA (Roto-Rooter) non-GAAP	$101.97M	Three Months Ended June 30, 2026	—

Adjusted EBITDA (VITAS) non-GAAP	$148.46M	Three Months Ended June 30, 2026	—
Adjusted EBITDA margin non-GAAP	21.1%	the second quarter of 2026	—

Adjusted EBITDA margin, excluding Medicare Cap non-GAAP	18.2%	the second quarter of 2026	—

Adjusted EBITDA, excluding Medicare Cap non-GAAP	$80.6M	the second quarter of 2026	—

Admissions	19,125	the second quarter of 2026	—

Average Daily Census (ADC)	23,687	the second quarter of 2026	—

Average daily census (Continuous care)	199	Three Months Ended June 30, 2026	—
Average daily census (Homecare)	19,249	Six Months Ended June 30, 2026	—
Average daily census (Inpatient)	326	Three Months Ended June 30, 2026	—
Average daily census (Total)	23,208	Six Months Ended June 30, 2026	—
Average length of stay (days)	101.9	Six Months Ended June 30, 2026	—

Average revenue per patient per day	$209.98	the second quarter of 2026	—

Days of revenue outstanding-excluding unapplied Medicare payments	39.7	Three Months Ended June 30, 2026	—

Days of revenue outstanding-including unapplied Medicare payments	26.9	Three Months Ended June 30, 2026	—

Estimated uncollectible accounts as a percent of revenues	0.7%	Three Months Ended June 30, 2026	—
Gross margin	50.4%	the second quarter of 2026	—
Gross margin, excluding Medicare Cap	23.9%	the second quarter of 2026	—
High acuity days-of-care as % of total days of care	2.2%	the second quarter of 2026	—

Median length of stay (days)	15	Six Months Ended June 30, 2026	—

Medicare Cap billing limitation accrued	$500,000	the second quarter of 2026	—

Medicare Cap billing limitation for provider numbers at limit	$7M	As of June 30, 2026	—
Medicare provider numbers with projected Cap cushion of 10% or greater	22	As of June 30, 2026	—
Reimbursement for high acuity care	$1,152.14	the second quarter of 2026	—

Reimbursement for routine home care	$188.62	the second quarter of 2026	—

Revenue from independent contractors	$17.1M	the second quarter of 2026	-2.0%

Roto-Rooter branch commercial revenue	$56.8M	the second quarter of 2026	—
Roto-Rooter branch residential revenue	$159.1M	the second quarter of 2026	—
Total Admissions	38,519	Six Months Ended June 30, 2026	—

Total Discharges	36,704	Six Months Ended June 30, 2026	—

Adjusted EBITDA margin (Roto-Rooter) non-GAAP	22.5%	first quarter of 2026	—
Gross margin (Roto-Rooter)	51%	first quarter of 2026	—
Gross margin, excluding Medicare Cap (VITAS)	22.9%	first quarter of 2026	—
Adjusted Diluted Earnings Per Share non-GAAP	$21.55	FY2025	—
Adjusted net income non-GAAP	311.58M	FY2025	—
GAAP → non-GAAP reconciliation GAAP Net income as reported 265.24M +32.67M Stock option expense +9.41M Amortization of reacquired franchise rights +5.63M Long-term incentive compensation +3.07M Legal settlements +3.72M Other -8.85M Tax impact of the above pre-tax adjustments +696K Excess tax benefits on stock compensation = Adjusted net income 311.58M
Average daily census ("ADC") - Homecare	18,533	Three Months Ended December 31	—
Average daily census ("ADC") - Total	22,462	Three Months Ended December 31	—
Days of care - Total	2,066,525	Three Months Ended December 31	—
EBITDA	422.37M	FY2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CHE Chemed Corp this stock	$6.84B	+22.3%	+4.1%	—	4.9%
HCA HCA Healthcare, Inc.	$93.03B	-10.5%	+7.1%	14.5	2.8%
FSNUY Fresenius SE & Co. KGaA	$30.21B	-6.9%	—	—	0.0%
THC Tenet Healthcare Corp	$21.48B	+34.3%	+0.9%	10.3	3.1%
FMS Fresenius Medical Care AG	$12.38B	-3.0%	+5.9%	—	0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

533

% held: 103.9%
Net QoQ: +382.4K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

467

View

Short & Settlement

Short Interest Rising

Shares short

638.4K

Days to cover: 3.7d
Change: +177.1K sh

View

Short Volume

Short vol %

64%

As of: Aug 28, 2026

Short Total

View

Fails to Deliver

FTD shares

2.4K

Value: $1.3M
As of: Jul 30, 2026

View

Off-Exchange

Off-exchange %

37.9%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$3.4M

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Congressional Trades Buy

Member

Lisa McClain

Amount: $1.0K–$15.0K
Traded: Jun 24, 2025

View

Financials

Revenue (FY)

$2.5B

Net income (FY): $265.2K
EPS diluted: $18.34

View

Buybacks

Authorized

$300.0M

Remaining: $139.8M

Spent Remaining

View

Filings

SEC Filings

Latest

10-Q

Filed: Jul 31, 2026
This year: 9

View

Proposed Sales

Value

$420.0K

Shares: 1.0K
Filed: May 1, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 29, 2026

View

Performance

	5D	20D	120D	MTD	YTD
CHE	-3.2%	-1.7%	+29.7%	-1.7%	+22.3%
SPY	+0.5%	+3.0%	+13.4%	+3.0%	+12.8%
vs SPY	-3.7%	-4.7%	+16.3%	-4.7%	+9.5%

Capital returns

Latest dividend

$0.70 / share · ex Aug 17, 2026

Raised 16.7%

Paid (TTM)

$2.50 / share · 4 payouts

Dividend yield (TTM, derived)

0.48%

Buyback program · as of Jul 31, 2026

Authorized

$300.00M

Spent (derived)

$160.20M

Remaining

$139.80M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 19584 CUSIP 16359R103 13F (30d) 402 filings 381 filers Visit website Investor relations

CHE · Chemed Corp

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns